Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?
Semaglutide will start losing patent protection in the near future.
Novo Nordisk, a pharmaceutical giant, has achieved success with its semaglutide-based drugs, Ozempic and Wegovy. These medicines have generated annual sales exceeding $1 billion, a benchmark many pharmaceutical companies aspire to. However, the success story has not been without challenges. In recent years, Ozempic and Wegovy have faced increased competition from various fronts.
In addition to this, Novo Nordisk's CEO, Mike Doustdar, recently highlighted a significant risk during the company's investor day - the looming patent cliff of semaglutide. This risk has caused investors to react negatively, leading to a 8% decline in Novo Nordisk's American Depositary Shares (ADSes) during a single day, marking the steepest drop in over six months.
Despite this recent setback, the dip could potentially present Novo Nordisk as a bargain buy for investors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
